News | Cath Lab | April 03, 2017

Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes

Minneapolis Heart Institute Foundation study finds that presence of cardiac arrest and/or cardiogenic shock is responsible for more than 75 percent of hospital deaths in STEMI patients

STEMI, cardiac arrest, cardiogenic shock, ACC.17 study, Minneapolis Heart Institute Foundation, MHIF

April 3, 2017 — The influence of cardiac arrest and cardiogenic shock on outcomes of patients with ST-elevation myocardial infarction (STEMI) has not been completely studied. Researchers at the Minneapolis Heart Institute Foundation (MHIF) conducted a study to determine the incidence, characteristics and outcomes of STEMI complicated by cardiac arrest with or without cardiogenic shock.

Prospective data from the Level I regional STEMI program at the Minneapolis Heart Institute at Abbott Northwestern Hospital was examined from March 2003 to December 2014. Researchers analyzed STEMI patients who had cardiac arrest prior to any intervention. They specifically sought to determine how the type of cardiac arrest (shockable versus non-shockable rhythm) and the presence of cardiogenic shock affect patient outcomes.

MHIF researchers, led by Benjamin Johnson, M.D., enrolled 4,511 patients in this study. The incidence of cardiac arrest prior to intervention was 11 percent. In-hospital death occurred in 250 (6 percent) of patients. Cardiac arrest was present in 56 percent and cardiogenic shock in 53 percent of these patients. In patients with shockable cardiac arrest, in-hospital mortality was 2.8x higher if they had cardiogenic shock as compared to no cardiogenic shock. In patients with non-shockable cardiac arrest, in-hospital mortality was equally high regardless of the presence of cardiogenic shock. Among this 4,511-patient cohort, cardiac arrest and/or cardiogenic shock accounted for 76 percent of all hospital deaths. 

Johnson noted, “Cardiac arrest and cardiogenic shock are associated with significantly increased morbidity and mortality in patients presenting with ST elevation myocardial infarction. Efforts need to be made to better understand this population of patients presenting with STEMI complicated by cardiac arrest with or without cardiogenic shock.”

Results of the study were presented at the American College of Cardiology Annual Scientific Session & Expo (ACC.17), March 17-19 in Washington, D.C.

Read about another cariogenic shock study presented at ACC.17., “New Protocol at Henry Ford Hospital Dramatically Increases Heart Attack Survival Rates.”

Watch the VIDEO "VIDEO: Cardiogenic Shock Supported With Impella Shows Good Outcomes."

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init